AICAR, Free Base CAS: [2627-69-2]
- Known as:
- AICAR, Free Base CAS: [2627-69-2]
- Catalog number:
- A-1098
- Product Quantity:
- 1 g
- Category:
- -
- Supplier:
- LCLabs
- Gene target:
- AICAR Free Base CAS: [2627-69-2]
Related genes to: AICAR, Free Base CAS: [2627-69-2]
- Gene:
- ACSS1 NIH gene
- Name:
- acyl-CoA synthetase short chain family member 1
- Previous symbol:
- ACAS2L
- Synonyms:
- dJ568C11.3, AceCS2L, MGC33843
- Chromosome:
- 20p11.21
- Locus Type:
- gene with protein product
- Date approved:
- 2001-07-17
- Date modifiied:
- 2019-03-22
- Gene:
- ACSS2 NIH gene
- Name:
- acyl-CoA synthetase short chain family member 2
- Previous symbol:
- ACAS2
- Synonyms:
- ACS, ACSA, AceCS, dJ1161H23.1
- Chromosome:
- 20q11.22
- Locus Type:
- gene with protein product
- Date approved:
- 2001-09-17
- Date modifiied:
- 2017-06-13
- Gene:
- AGO2 NIH gene
- Name:
- argonaute RISC catalytic component 2
- Previous symbol:
- EIF2C2, CASC7
- Synonyms:
- hAGO2, Q10, LINC00980
- Chromosome:
- 8q24.3
- Locus Type:
- gene with protein product
- Date approved:
- 2000-01-14
- Date modifiied:
- 2019-02-01
- Gene:
- ASPH NIH gene
- Name:
- aspartate beta-hydroxylase
- Previous symbol:
- -
- Synonyms:
- CASQ2BP1, BAH, JCTN, HAAH
- Chromosome:
- 8q12.3
- Locus Type:
- gene with protein product
- Date approved:
- 1995-06-13
- Date modifiied:
- 2016-10-05
- Gene:
- ATIC NIH gene
- Name:
- 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase
- Previous symbol:
- -
- Synonyms:
- PURH, AICARFT, IMPCHASE
- Chromosome:
- 2q35
- Locus Type:
- gene with protein product
- Date approved:
- 1997-05-15
- Date modifiied:
- 2014-11-19
Related products to: AICAR, Free Base CAS: [2627-69-2]
Paliperidone N-Oxide C23H27FN4O4 CAS: 761460-08-6 Paliperidone N-Oxide CAS: 761460-08-6 Formula: C23H27FN4O4 2,4-Dibromo-17,17-ethylenedioxy-1,3,5(10)-estratriene-3,16α-diol C20H24Br2O4 CAS: 90474-20-7 2,4-Dibromo-17,17-ethylenedioxy-1,3,5(10)-estratriene-3,16α-diol CAS: 90474-20-7 Formula: C20H24Br2O4 2,4-Dibromo-17,17-ethylenedioxy-1,3,5(10)-estratriene-3-ol C20H24Br2O3 CAS: 2,4-Dibromo-17,17-ethylenedioxy-1,3,5(10)-estratriene-3-ol CAS: Formula: C20H24Br2O3 3,3',5,5'-Tetraiodo Thyroformic Acid C13H6I4O4 CAS: 2055-97-2 3,3',5,5'-Tetraiodo Thyroformic Acid CAS: 2055-97-2 Formula: C13H6I4O4 3,5,3',5'-Tetrachlorobisphenol A C15H12Cl4O2 CAS: 79-95-8 3,5,3',5'-Tetrachlorobisphenol A CAS: 79-95-8 Formula: C15H12Cl4O2 4-(2,6,6-Trimethyl-2-cyclohexen-1-ylidene)-2-acetoxybut-2-ene C15H22O2 CAS: 61693-39-8 4-(2,6,6-Trimethyl-2-cyclohexen-1-ylidene)-2-acetoxybut-2-ene CAS: 61693-39-8 Formula: C15H22O2 4-Benzyloxy-1-cyclohexanecarbonitrile (cis / trans mixture) CAS: 95233-32-2 Formula: C14H17NO 4-Benzyloxy-1-cyclohexanecarbonitrile (cis _ trans mixture) C14H17NO CAS: 95233-32-2 5-[(4-Methoxyphenyl)-diphenylmethylamino-6-methoxy-9H-purin-9-yl]-13C2, 15N-3-(phenylmethoxy)-2-[(phenylmethoxy)methyl]-cyclopentanol CAS: Formula: Related articles to: AICAR, Free Base CAS: [2627-69-2]
- Short peripheral intravenous catheter (PIVC) failure is a common complication that is generally underdiagnosed. Some studies have evaluated the factors associated with these complications, but the impact of care complexity individual factors and nurse staffing levels on PIVC failure is still to be assessed. The aim of this study was to determine the incidence and risk factors of PIVC failure in the public hospital system of the Southern Barcelona Metropolitan Area. - Source: PubMed
Publication date: 2024/05/09
Jiménez-Martínez EmilioAdamuz JordiGonzález-Samartino MaribelMuñoz-Carmona Maria AntoniaHornero AnaMartos-Martínez M PurificacionMembrive-Martínez RemediosJuvé-Udina Maria-Eulàlia - This study examined the association of socio-economic factors and the structure of primary care centres (PCCs) with measles, mumps, and rubella (MMR) vaccination coverage among the 8-year-old population in Catalonia, Spain. We conducted an ecological study to retrospectively assess the MMR vaccination-recorded status of children born in 2012, using public health data extracted in December 2020. For each of 300 PCCs serving 70,498 children, we calculated vaccination coverage rates from electronic health records and linked these rates to a composite deprivation index corresponding to the territory served by each PCC. We identified a relationship between unfavourable socio-economic factors and higher recorded vaccination coverage. On average, directly managed PCCs had higher vaccination coverage rates than indirectly managed PCCs. Greater utilisation of primary care services by the population was also associated with higher vaccination coverage rates. Further research is needed to generate knowledge valuable for informing more equitable child-vaccination service delivery models. - Source: PubMed
Publication date: 2024/04/25
Martínez-Marcos MontseReñé-Reñé AnnaZabaleta-Del-Olmo EdurneGuiriguet CarolinaGómez-Durán Esperanza-LCabezas-Peña Carmen - An inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal neoplasm of borderline malignant potential. Nearly half of all IMTs have rearrangement of anaplastic lymphoma kinase (ALK) locus on chromosome 2p23 which can be treated with targeted therapy. Herein, we describe an unusual presentation of IMT involving an anatomical region rarely implicated in this disease process. A 15-year-old male patient came to the ER with dysphagia and coffee ground emesis. On esophagogastroscopy, a nodular luminal obstructing 30 × 50 mm mass in the lower esophagus was found, which was continuous with a large, partially circumferential gastric mass extending from the mid-body to the proximal antrum. Biopsies from esophageal and gastric masses revealed submucosal lesions composed of cytologically bland spindle and epithelioid cells, intermingled with inflammatory infiltrate, for which several immunohistochemical (IHC) stains were performed. The molecular study demonstrated ATIC::ALK fusion. Based on morphological, IHC, and molecular study findings, the diagnosis of ALK-positive IMT was rendered. Because surgical excision was deemed infeasible, the patient was started on ALK-inhibiting therapy with crizotinib. The patient responded well with no evidence of residual or recurrent disease on follow-up imaging or surveillance esophagogastroduodenoscopy. Crizotinib was ultimately discontinued after 10 months of therapy, and the patient continues to undergo surveillance imaging for monitoring of disease burden. - Source: PubMed
Publication date: 2024/04/24
Billingsley Benjamin CChaudhary RiticaMorris Michael WCox Jennifer ACamacho-Gomez Sandra MVarshney Neha - Metabolic reprogramming is currently considered a hallmark of tumor and immune development. It is obviously of interest to identify metabolic enzymes that are associated with clinical prognosis in head and neck squamous cell carcinomas (HNSCC). - Source: PubMed
Publication date: 2024/04/16
Wang LuHe YeBai YijiangZhang ShuaiPang BoChen AnhaiWu Xuewen - The MCS initiative was first introduced in 2013. Since then, two MCS papers have been published: the first proposing a structured approach to consider the impact of drug substance physical properties on manufacturability and the second outlining real world examples of MCS principles. By 2023, both publications had been extensively cited by over 240 publications. This article firstly reviews this citing work and considers how the MCS concepts have been received and are being applied. Secondly, we will extend the MCS framework to continuous manufacture. The review structure follows the flow of drug product development focussing first on optimisation of API properties. The exploitation of links between API particle properties and manufacturability using large datasets seems particularly promising. Subsequently, applications of the MCS for formulation design include a detailed look at the impact of percolation threshold, the role of excipients and how other classification systems can be of assistance. The final review section focusses on manufacturing process development, covering the impact of strain rate sensitivity and modelling applications. The second part of the paper focuses on continuous processing proposing a parallel MCS framework alongside the existing batch manufacturing guidance. Specifically, we propose that continuous direct compression can accommodate a wider range of API properties compared to its batch equivalent. - Source: PubMed
Publication date: 2024/05/06
Leane MichaelPitt KendalReynolds GavinTantuccio AnthonyMoreton ChrisCrean AbinaKleinebudde PeterCarlin BrianGamble JohnGamlen MichaelStone ElaineKuentz MartinGururajan BindhuKhimyak Yaroslav ZVan Snick BerndAndersen SuneMisic ZdravkaPeter StefanieSheehan Stephen